6α-Methylprednisolone 21-hemisuccinate sodium salt , 98% , 2375-03-3

Synonym(s):
6α-Methyl-11β,17α,21-trihydroxy-1,4-pregnadiene-3,20-dione 21-hemisuccinate;6α-Methylprednisolone sodium succinate;MPSL

CAS NO.：2375-03-3

Empirical Formula: C26H33O8.Na

Molecular Weight: 496.53

MDL number: MFCD00152612

EINECS: 219-156-8

PRODUCT Properties

• Melting point: >186°C (dec.)
• storage temp.: Inert atmosphere,Room Temperature
• solubility: DMSO (Slightly), Methanol (Slightly)
• form: lyophilized powder
• color: White to Off-White
• InChIKey: FQISKWAFAHGMGT-JXAFMBTDNA-M
• SMILES: [C@]12(C[C@@H](C3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@H](C[C@]1(C)[C@@](CC[C@@]21[H])(O)C(=O)COC(=O)CCC([O-])=O)O)C)[H].[Na+] |&1:0,2,9,11,13,15,17,20,r|

Description and Uses

Methylprednisolone Sodium Succinate is the sodium succinate salt of a synthetic glucocorticoid receptor agonist with immunosuppressive and anti-inflammatory effects. It is converted into active prednisolone in the body, which activates glucocorticoid receptor-mediated gene expression. This includes inducing the synthesis of the anti-inflammatory protein IkappaB-alpha and inhibiting the synthesis of nuclear factor kappa B (NF-kappaB). As a result, proinflammatory cytokine production, such as IL-1, IL-2, and IL-6, is down-regulated, and cytotoxic T-lymphocyte activation is inhibited. Therefore, an overall reduction in chronic inflammation and autoimmune reactions may be achieved.

6α-Methylprednisolone 21-Hemisuccinate is a glucocorticosteroid used in anti-inflammatory medication in the treatment of spinal cord injuries.

Safety

• Symbol(GHS): GHS08
• Signal word: Danger
• Hazard statements: H351-H360
• Precautionary statements: P201-P308+P313
• Hazard Codes: T
• Risk Statements: 61-40
• Safety Statements: 53-22-36/37/39-45
• WGK Germany: 3
• RTECS: TU4154060
• Toxicity: LD50 oral in rat: > 5gm/kg